1 / 17

CE marking and European IVD Directive

CE marking and European IVD Directive. Current regulatory system Joint Action Plan Signal Detection Proposals for change Classification Clinical e vidence In house manufacturing Companion diagnostics. Medical device regulations. investigation action. Competent Authority.

mariettat
Download Presentation

CE marking and European IVD Directive

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CE marking and European IVD Directive

  2. Current regulatory system • Joint Action Plan • Signal Detection Proposals for change • Classification • Clinical evidence • In house manufacturing • Companion diagnostics

  3. Medical device regulations investigation action Competent Authority Notified Body compliance post market surveillance vigilance European market Harmonised Standards/CTS “presumption of conformity”

  4. Joint Action Plan • Qualifications of NB re-assessed • Joint Audits of NB • Unannounced visits of manufacturers • Vigilance teleconference of Competent Authorities

  5. Signal Detection • Significant improvements in adverse incident reporting by UK healthcare • New signal detection software • Increased focus on signals

  6. Proposed new regulations • Proposals published in September 2012 • Medical Devices Regulation • IVD Regulation • Move to risk-based classification rules • Clinical evidence & clinical investigation requirements • Changes to ‘in-house’ exemption • Companion diagnostics • Many other aspects aligned across both regulations (notified bodies, unique device identifiers)

  7. Classification rules • IVDs are currently categorised into two main lists: • high risk tests used in blood screening, • a mixed list of other medium risk tests • home tests, and • all other tests • New system will use rules to classify devices as A, B, C or D

  8. RISK

  9. Clinical Evidence • Clinical evidence now required (though exceptions possible) – documented in a clinical evidence report • Concepts of analytical performance scientific validity, and clinical performance introduced • Post-market surveillance required to keep clinical evidence up to date

  10. Clinical Evidence - Terminology Analytical performance: the ability of an IVD to detect or measure a particular analyte Scientific validity: the association of an analyte to a clinical condition or a physiological state Clinical performance: the ability of an IVD to give results that are related to the clinical condition/ physiological state in the target population and intended user

  11. Clinical evidence vs clinical utility Scientific Validity CLINICAL UTILITY CLINICAL EVIDENCE Clinical Performance Analytical Performance

  12. Clinical performance studies • New concept – when gathering data to support CE marking • General requirements on all studies • Specific requirements – including competent authority approval – on: • ‘interventional’ studies – affecting patient management decisions; and • studies that involve invasive procedures or other risks for patients.

  13. The ‘in-house’ exemption • Currently – blanket exemption for all IVDs manufactured and used within same health institution • Commission’s proposal: • single quality management system • accreditation to ISO 15189 • vigilance reporting • exclusion of highest risk (‘class D’) IVDs

  14. Companion Diagnostics • Class C • “specifically intended to select patients with a previously diagnosed condition or predisposition as eligible for a targeted therapy” • The Notified Body will consult with the county’s medicines authority

  15. Thank you for listening Steve Lee 020 3080 7309 Stephen.Lee@mhra.gsi.gov.uk

More Related